Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

Publisher： Karger

E-ISSN： 1664-5553|2|2|93-107

ISSN： 2235-1795

Source： Liver Cancer, Vol.2, Iss.2, 2013-04, pp. : 93-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

By  

Liver Cancer, Vol. 4, Iss. 3, 2015-09 ,pp. : I-VII

Karger

Access to resources Recommend Favorite

Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis

By  

Digestion, Vol. 83, Iss. 4, 2011-02 ,pp. : 275-282

Karger

Access to resources Recommend Favorite

Combination of Local Transcatheter Arterial Chemoembolization and Systemic Anti-Angiogenic Therapy for Unresectable Hepatocellular Carcinoma

By  

Liver Cancer, Vol. 1, Iss. 3-4, 2012-11 ,pp. : 201-215

Karger

Access to resources Recommend Favorite

Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives

By Shen Ying-Chun   Hsu Chiun   Cheng Ann-Lii  

Journal of Gastroenterology, Vol. 45, Iss. 8, 2010-08 ,pp. : 794-807

Springer Publishing Company

Access to resources Recommend Favorite

Are Biomarkers Still Helpful in Hepatocellular Carcinoma?

By  

Digestion, Vol. 87, Iss. 2, 2013-02 ,pp. : 118-120

Karger

Access to resources Recommend Favorite